Vasiliki Tasouli-Drakou

Dr. Vasiliki Tasouli-Drakou

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
IOIan Ogurek
Ian Ogurek
TSTaha Shaikh
Taha Shaikh
MRMarc Ringor
Marc Ringor
MDMichael DiCaro
Michael DiCaro
KLKaChon Lei
KaChon Lei
Atherosclerosis, a condition characterized by the accumulation of lipids and a culprit behind cardiovascular events, has long been studied. However, in recent years, there has been an increase in interest in its initiation, with researchers shifting focus from traditional pathways involving the vascular infiltration of oxidized lipids and towards the novel presence of chronic inflammatory pathways. The accumulation of pro-inflammatory cytokines, in combination with the activation of transcription factors, creates a positive feedback loop that drives the creation and progression of atherosclerosis. From the upregulation of the nod-like receptor protein 3 (NLRP3) inflammasome and the Notch and Wnt pathways to the increased expression of VEGF-A and the downregulation of connexins Cx32, Cx37, and Cx40, these processes contribute further to endothelial dysfunction and plaque formation. Herein, we aim to provide insight into the molecular pathways and mechanisms implicated in the initiation and progression of atherosclerotic plaques, and to review the risk factors associated with their development.

21 November 2022 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
MNMay Nguyen
May Nguyen
HGHannah Guinn
Hannah Guinn
OHOmron Hassan
Omron Hassan
SBSneha Butala
Sneha Butala
SPSheshanna Phan
Sheshanna Phan
Febrile ulceronecrotic Mucha-Habermann Disease (FUMHD) is a variant of Pityriasis Lichenoides Et Varioliformis Acuta (PLEVA). Although rare, the condition may progress to involve serious complications and even lead to fatal outcomes if diagnosis and appropriate treatment is delayed. A PubMed search following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines was performed to find cases of FUMHD from the earliest records to October 2021. Treatments, complications, and patient outcomes were extracted from the literature and summarized, while a review of quality was also performed. A total of 63 publications with 68 patients were found. Successful treatment modalities for FUMHD included antibiotics, antivirals, systemic steroids, methotrexate (MTX), cyclophosphamide, cyclosporine (CYA), intravenous immunoglobulins (IVIG), pentoxifylline, and ultraviolet B phototherapy. Out of 68 patients, 55 patients had their condition fully resolved and 13 cases were fatal. Increased age, systemic involvement, and monoclonal T-cell receptor rearrangement were associated with worst prognosis, but mucosal involvement did not affect mortality risk. Overall, the publications had low risk of bias, but most lacked adequate follow-up periods. FUMHD is a diagnostic and therapeutic challenge due to the lack of clearly defined diagnostic criteria and optimum treatment. Further studies with larger patient populations and longer follow-up periods may lead to refinement of diagnostic criteria, establish an optimum treatment regimen, and better estimate the likelihood of recurrence.

29 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASArsalan Siddiqui
Arsalan Siddiqui
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
MRMarc Ringor
Marc Ringor
MDMichael DiCaro
Michael DiCaro
BYBrianna Yee
Brianna Yee
TTTahir Tak
Tahir Tak
Cardiac Resynchronization Therapy (CRT) has been established as a major component of heart failure management, resulting in a significant reduction in patient morbidity and death for patients with increased QRS duration, low left ventricular ejection fraction (LVEF), and high risk of arrhythmias. The ability to synchronize both ventricles, lower heart failure hospitalizations, and optimize clinical outcomes are some of the attractive characteristics of biventricular pacing, or CRT. However, the high rate of CRT non-responders has led to the development of new modalities including leadless CRT pacemakers (CRT-P) and devices focused on conduction system pacing (CSP). This comprehensive review aims to present recent findings from CRT clinical trials and systematic reviews that have been published that will likely guide future directions in patient care.

29 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IOIan Ogurek
Ian Ogurek
RGRandeep Gill
Randeep Gill
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
RJRonnie Joseph
Ronnie Joseph
AKArbab Khalid
Arbab Khalid
TTTahir Tak
Tahir Tak
Hypertrophic cardiomyopathy is the most prevalent inherited cardiac condition, distinguished by an autosomal dominant inheritance pattern. Diagnosis can be achieved through echocardiography, cardiac magnetic resonance imaging, and genetic testing. Recently, significant advancements have occurred in pharmacological and invasive therapies that are transforming the management of hypertrophic cardiomyopathy, including the introduction of cardiac myosin inhibitors, radiofrequency ablation, and gene editing. Additional trials are being conducted on investigational therapies, with the results anticipated in the near future. This review aims to provide a concise overview of both currently approved and investigational treatments for hypertrophic cardiomyopathy.

9 August 2023 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
LDLaura Duzett
Laura Duzett
GMGuadalupe Mercado
Guadalupe Mercado
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
AKAlicia Kane
Alicia Kane
ATAlison Tam
Alison Tam
In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced. However, there has not been a systematic review that investigates pityriasis eruptions and the associated variants following COVID-19 inoculations. A PubMed search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed to find case reports from the earliest record through November 2022. Data including types of vaccination and pityriasis were extracted and a quality review was performed. 47 reports with 94 patients were found: 64.9% had pityriasis rosea (PR), 3.2% PR-like eruptions, 16.0% pityriasis rubra pilaris (PRP), 7.4% pityriasis lichenoides et varioliformis acuta (PLEVA), 3.2% pityriasis lichenoides chronica (PLC), and 5.3% had reactions described as “atypical”. The top three COVID-19 vaccinations reported were Pfizer-BioNTech (47.9%), Oxford-AstraZeneca (11.7%), and Moderna (8.5%). Pityriasis reactivity was reported most frequently after the Pfizer-BioNTech vaccination, with pityriasis rosea being the most common variant. A large difference was additionally found between the ratio of post-vaccination pityriasis reactions following Pfizer and Moderna vaccinations (5.63), and the ratio of Pfizer’s usage in the United States as of December 28, 2022 relative to that of Moderna (1.59). Further studies with adequate follow-up periods and diagnostic testing will thus need to be performed to elucidate the root of this discrepancy and better characterize the association between different pityriasis reactions and COVID-19 vaccinations.

1 July 2025 in International Journal of Angiology
Verified
Journal Article
Closed access
MMMohamad Mubder
Mohamad Mubder
NRNoyan Ramazani
Noyan Ramazani
VTVasiliki Tasouli-Drakou
Vasiliki Tasouli-Drakou
NHNazanin Houshmand
Nazanin Houshmand
TTTahir Tak
Tahir Tak
Coronary artery aneurysm (CAA) is a focal enlargement of the coronary artery exceeding 1.5 times the diameter of the adjacent normal segment of the vessel. The reported prevalence of CAA varies widely from 0.2 to 10%, with male predominance and a predilection for the right coronary artery. Atherosclerosis is the main cause in adults and Kawasaki disease in children. While often asymptomatic, CAA may present with angina, myocardial infarction, or possible fatal complications such as rupture, compression of adjacent cardiopulmonary structures, thrombus formation, and distal embolization. CAA is usually an incidental finding during coronary angiography; however, advancements in cardiac imaging have enhanced the detection and characterization of CAA. Coronary computed tomography angiography and magnetic resonance angiography offer alternatives to traditional approaches with high-resolution images that can help with risk stratification and management planning. Management varies based on the size, location, complications, and presence of symptoms. It includes medical therapy, percutaneous intervention, and surgical approach. In this paper, we aim to provide a comprehensive review of current knowledge of CAA and recent advances in its diagnosis and management.